According to the study, users of the drugs seem to be at a higher risk, not lower, of developing a cognitive impairment ...

Although GLP-1 analogs were associated with increased risks for cognitive impairment, they had a larger, protective effect ...

By extending survival, GLP-1 agents may expand the dementia risk period for diabetes patie ...

The majority of weight loss from GLP-1 medication is from fat loss, and not muscle loss, new evidence suggests.

As many of us know, keeping weight in check can be hard. National numbers certainly reflect this. Rates of overweight and ...

Stopping popular GLP-1 weight-loss drugs may reverse much of their benefit within a year, according to a large modeling analysis, raising questions about how long patients may need to stay on ...

New research has reignited debate over whether GLP-1 receptor agonists, widely prescribed for diabetes and weight loss, affect cognitive health. While some studies link these drugs to lower dementia ...

FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 ...

The field of obesity management has been significantly advanced by the introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which have ...

Could drugs like Mounjaro treat people with cannabis use disorder? They might. Preliminary research indicates they may stop ...

The Drugs Consultative Committee (DCC), during its 68th meeting, deliberated on strengthening regulatory oversight and ...

A hormone called FGF21 can reverse obesity in mice by activating a newly identified brain circuit tied to metabolism. Surprisingly, it works in the hindbrain—the same region targeted by GLP-1 drugs ...